Correlation of serum ZO-1 with biochemical parameters and disease severity in DCAC patients with HRS
Parameters
Pearson correlation coefficient
p value
Creatinine
0.590
< 0.0001
Urea
0.497
< 0.0001
Total protein
–0.486
< 0.0001
Albumin
–0.779
< 0.0001
AST
0.436
< 0.0001
ALT
0.257
< 0.05
γGT
0.384
< 0.001
ALP
0.563
< 0.0001
Total bilirubin
0.515
< 0.0001
Direct bilirubin
0.439
< 0.0001
Sodium
–0.495
< 0.0001
Potassium
0.081
0.449
Chloride
–0.035
0.761
PT
0.488
< 0.0001
INR
0.559
< 0.0001
Child-Pugh score
0.708
< 0.0001
MELD score
0.419
< 0.0001
MELD-Na
0.849
< 0.0001
ZO-1: zonula occludens-1; DCAC: decompensated alcoholic cirrhosis; HRS: hepatorenal syndrome; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; γGT: gamma-glutamyl transferase; INR: international normalized ratio; MELD: model for end-stage liver disease; PT: prothrombin time
Declarations
Author contributions
BV: Conceptualization, Resources, Supervision, Formal analysis, Validation, Writing—original draft, Writing—review & editing. RK: Methodology, Data curation, Formal analysis. MW: Investigation, Supervision. All authors read and approved the final manuscript.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Ethical approval
This study was reviewed and approved by the JIPMER scientific advisory committee and Institute Ethics Committee for human studies [JIP/IEC/2019/499].
Consent to participate
All patients were provided with informed written consent regarding the data collection and scientific publication.
Consent to publication
Not applicable.
Availability of data and materials
The raw data underlying this article will be shared on reasonable request to the corresponding author.
Funding
This work was supported by the JIPMER intramural research grant [Phase-I/2020-2021/MSc/23]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Pose E, Piano S, Juanola A, Ginès P. Hepatorenal Syndrome in Cirrhosis.Gastroenterology. 2024;166:588–604.e1. [DOI] [PubMed]
Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome.Nat Rev Dis Primers. 2018;4:23. [DOI] [PubMed]
R MR, Delgado AF, Zubiria AD, Pinto R, Hoz-Valle JADl, Pérez-Riveros ED, et al. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia.PLoS One. 2020;15:e0239834. [DOI] [PubMed] [PMC]
Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [DOI] [PubMed]
Ng CKF, Chan MHM, Tai MHL, Lam CWK. Hepatorenal syndrome.Clin Biochem Rev. 2007;28:11–7. [PubMed] [PMC]
Arora MS, Kaushik R, Ahmad S, Kaushik RM. Profile of Acute Kidney Injury in Patients with Decompensated Cirrhosis at a Tertiary-Care Center in Uttarakhand, India.Dig Dis. 2020;38:335–43. [DOI] [PubMed]
Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation.J Hepatol. 2012;57:203–12. [DOI] [PubMed]
Adachi M, Tanaka A, Aiso M, Takamori Y, Takikawa H. Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis.Hepatol Res. 2015;45:1299–306. [DOI] [PubMed]
Francoz C, Sola E. Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.J Hepatol. 2019;70:828–30. [DOI] [PubMed]
Kar S, Paglialunga S, Islam R. Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies.J Clin Pharmacol. 2018;58:1239–47. [DOI] [PubMed]
Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis.Hepatol Int. 2011;5:927–33. [DOI] [PubMed]
Yoo J, Kim SG, Kim YS, Lee B, Lee MH, Jeong SW, et al. Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.J Hepatol. 2019;70:847–54. [DOI] [PubMed]
Gomaa SH, Shamseya MM, Madkour MA. Clinical utility of urinary neutrophil gelatinase-associated lipocalin and serum cystatin C in a cohort of liver cirrhosis patients with renal dysfunction: a challenge in the diagnosis of hepatorenal syndrome.Eur J Gastroenterol Hepatol. 2019;31:692–702. [DOI] [PubMed]
Raya-Sandino A, Lozada-Soto KM, Rajagopal N, Garcia-Hernandez V, Luissint A, Brazil JC, et al. Claudin-23 reshapes epithelial tight junction architecture to regulate barrier function.Nat Commun. 2023;14:6214. [DOI] [PubMed] [PMC]
Gonzalez-Mariscal L, Namorado MC, Martin D, Luna J, Alarcon L, Islas S, et al. Tight junction proteins ZO-1, ZO-2, and occludin along isolated renal tubules.Kidney Int. 2000;57:2386–402. [DOI] [PubMed]
Xu X, Zhang X, Gao L, Liu C, You K. Neonatal Hyperoxia Downregulates Claudin-4, Occludin, and ZO-1 Expression in Rat Kidney Accompanied by Impaired Proximal Tubular Development.Oxid Med Cell Longev. 2020;2020:2641461. [DOI] [PubMed] [PMC]
Eadon MT, Hack BK, Xu C, Ko B, Toback FG, Cunningham PN. Endotoxemia alters tight junction gene and protein expression in the kidney.Am J Physiol Renal Physiol. 2012;303:F821–30. [DOI] [PubMed] [PMC]
Wei W, Li W, Yang L, Weeramantry S, Ma L, Fu P, et al. Tight junctions and acute kidney injury.J Cell Physiol. 2023;238:727–41. [DOI] [PubMed]
Mohanty A, Garcia-Tsao G. Hyponatremia and Hepatorenal Syndrome.Gastroenterol Hepatol (N Y). 2015;11:220–9. [PubMed] [PMC]
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list.N Engl J Med. 2008;359:1018–26. [DOI] [PubMed] [PMC]
Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease.Aliment Pharmacol Ther. 2007;26:141–8. [DOI] [PubMed]
Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.Hepatology. 2017;66:1232–41. [DOI] [PubMed]
Seo YS, Park SY, Kim MY, Kim SG, Park JY, Yim HJ, et al. Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites.J Gastroenterol Hepatol. 2018;33:910–7. [DOI] [PubMed]
Kim DJ, Kang HS, Choi HS, Cho HJ, Kim ES, Keum B, et al. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels.Korean J Hepatol. 2011;17:130–8. [DOI] [PubMed] [PMC]
Gerbes AL, Gülberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver.Gut. 2002;50:106–10. [DOI] [PubMed] [PMC]
Ahn HS, Kim YS, Kim SG, Kim HK, Min SK, Jeong SW, et al. Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels.Hepatogastroenterology. 2012;59:1168–73. [DOI] [PubMed]
Xiong C, Zang X, Zhou X, Liu L, Masucci MV, Tang J, et al. Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.Oncotarget. 2017;8:31238–53. [DOI] [PubMed] [PMC]
Karthikeyan A, Mohan P, Chinnakali P, Vairappan B. Elevated systemic zonula occludens 1 is positively correlated with inflammation in cirrhosis.Clin Chim Acta. 2018;480:193–8. [DOI] [PubMed]
Ram AK, Pottakat B, Vairappan B. Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma.BMC Cancer. 2018;18:572. [DOI] [PubMed] [PMC]
Fu J, Lee K, Chuang PY, Liu Z, He JC. Glomerular endothelial cell injury and cross talk in diabetic kidney disease.Am J Physiol Renal Physiol. 2015;308:F287–97. [DOI] [PubMed] [PMC]
